[go: up one dir, main page]

MX2016009911A - Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes. - Google Patents

Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.

Info

Publication number
MX2016009911A
MX2016009911A MX2016009911A MX2016009911A MX2016009911A MX 2016009911 A MX2016009911 A MX 2016009911A MX 2016009911 A MX2016009911 A MX 2016009911A MX 2016009911 A MX2016009911 A MX 2016009911A MX 2016009911 A MX2016009911 A MX 2016009911A
Authority
MX
Mexico
Prior art keywords
glycosilation
modulate
overprinting
regulators
route
Prior art date
Application number
MX2016009911A
Other languages
English (en)
Other versions
MX377780B (es
Inventor
Kang Sohye
Gupta Shivani
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016009911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016009911A publication Critical patent/MX2016009911A/es
Publication of MX377780B publication Critical patent/MX377780B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan métodos para modular las propiedades de un cultivo de células que expresa una proteína de interés. En varias modalidades los métodos se refieren a la sobreexpresión de las proteínas implicadas en la ruta de N-glicosilación.
MX2016009911A 2014-01-29 2014-12-11 Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes. MX377780B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29
PCT/US2014/069744 WO2015116315A1 (en) 2014-01-29 2014-12-11 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Publications (2)

Publication Number Publication Date
MX2016009911A true MX2016009911A (es) 2016-10-28
MX377780B MX377780B (es) 2025-03-11

Family

ID=53757626

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009911A MX377780B (es) 2014-01-29 2014-12-11 Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
MX2020012356A MX2020012356A (es) 2014-01-29 2016-07-29 Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012356A MX2020012356A (es) 2014-01-29 2016-07-29 Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.

Country Status (14)

Country Link
US (3) US10227627B2 (es)
EP (1) EP3099806A1 (es)
JP (4) JP6474420B2 (es)
KR (3) KR102301034B1 (es)
CN (2) CN113774084B (es)
AU (3) AU2014380174C1 (es)
BR (1) BR112016017606A2 (es)
CA (1) CA2938079C (es)
CL (1) CL2016001900A1 (es)
EA (2) EA037565B1 (es)
IL (3) IL282517B (es)
MX (2) MX377780B (es)
SG (1) SG10201912081RA (es)
WO (1) WO2015116315A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
AU2018235928B2 (en) * 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
BR112021024923A2 (pt) * 2019-06-10 2022-02-15 Cho Plus Inc Métodos de preparação de uma linha celular, de produção de um produto farmacêutico, de obtenção de uma linha celular e de produção de uma proteína, linhas celulares produtora e híbrida, sistema para produção de alto nível de produtos farmacêuticos, e, produto farmacêutico
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CA3218684A1 (en) * 2021-05-03 2022-11-10 Boehringer Ingelheim International Gmbh Method for producing spesolimab
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ATE503013T1 (de) 1995-06-29 2011-04-15 Immunex Corp Cytokin welches apoptose induziert
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CN1930281A (zh) 2004-03-05 2007-03-14 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
WO2010122460A1 (en) * 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011109600A1 (en) * 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
US9921210B2 (en) * 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
TW201209160A (en) * 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
SG11201403814RA (en) 2012-01-11 2014-10-30 Sigma Aldrich Co Llc Production of recombinant proteins with simple glycoforms

Also Published As

Publication number Publication date
KR20220086703A (ko) 2022-06-23
MX377780B (es) 2025-03-11
EA037565B1 (ru) 2021-04-14
AU2014380174B2 (en) 2018-08-30
IL246914A0 (en) 2016-09-29
US20200277642A1 (en) 2020-09-03
AU2020239681C1 (en) 2025-06-05
US10227627B2 (en) 2019-03-12
AU2018264100B2 (en) 2020-07-23
AU2020239681B2 (en) 2022-06-23
JP2022068365A (ja) 2022-05-09
EP3099806A1 (en) 2016-12-07
CL2016001900A1 (es) 2017-05-12
JP6797950B2 (ja) 2020-12-09
SG10201912081RA (en) 2020-02-27
US20190010532A1 (en) 2019-01-10
EA202190244A3 (ru) 2021-08-31
JP2017505620A (ja) 2017-02-23
WO2015116315A1 (en) 2015-08-06
KR20160111943A (ko) 2016-09-27
AU2020239681A1 (en) 2020-10-15
MX2020012356A (es) 2021-01-29
CN113774084B (zh) 2024-04-16
CN106170554A (zh) 2016-11-30
KR102519540B1 (ko) 2023-04-10
CA2938079C (en) 2022-10-11
AU2014380174A1 (en) 2016-08-11
CN113774084A (zh) 2021-12-10
AU2014380174C1 (en) 2025-06-05
IL270861A (en) 2020-01-30
IL246914B (en) 2019-12-31
AU2018264100A1 (en) 2018-12-06
CA2938079A1 (en) 2015-08-06
BR112016017606A2 (pt) 2017-10-10
JP2021040638A (ja) 2021-03-18
KR20210114549A (ko) 2021-09-23
US10907186B2 (en) 2021-02-02
CN106170554B (zh) 2021-08-17
EA202190244A2 (ru) 2021-05-31
JP2019088305A (ja) 2019-06-13
EA201691532A1 (ru) 2017-01-30
KR102410393B1 (ko) 2022-06-16
JP7788307B2 (ja) 2025-12-18
US20190153496A1 (en) 2019-05-23
IL282517A (en) 2021-06-30
JP7034236B2 (ja) 2022-03-11
IL270861B (en) 2021-05-31
AU2018264100C1 (en) 2025-06-05
US10655156B2 (en) 2020-05-19
IL282517B (en) 2022-07-01
KR102301034B1 (ko) 2021-09-13
JP6474420B2 (ja) 2019-02-27

Similar Documents

Publication Publication Date Title
MX2016009911A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
IL297617B1 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
CY1124108T1 (el) Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
GEAP202114450A (en) Anti-tigit antibodies
EP3108229A4 (en) Nanopore-based analysis of protein characteristics
EP3217807A4 (en) Methods and compositions for egg white protein production
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
UY34885A (es) Proteínas de unión anti-mesotelina
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX375352B (es) Reguladores de nrf2.
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
AR102350A1 (es) Inmunomoduladores
MX375524B (es) Anticuerpos anti-axl.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX377774B (es) Formulaciones de proteinas.
NI201600127A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA.
EP3448884C0 (en) Engineered mammalian cells for production of recombinant proteins

Legal Events

Date Code Title Description
FG Grant or registration